PSIL 002
Alternative Names: PSIL-002Latest Information Update: 29 Aug 2022
At a glance
- Originator Psilera
- Class Antidepressants; Dimethylamines; Drug withdrawal therapies; Mood stabilisers; Small molecules; Tryptamines
- Mechanism of Action 5-HT1 serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders; Mood disorders; Neurodegenerative disorders; Substance-related disorders
Most Recent Events
- 10 Aug 2022 Preclinical trials in Depressive disorders in USA (unspecified route) prior to August 2022
- 10 Aug 2022 Preclinical trials in Neurodegenerative disorders in USA (unspecified route) prior to August 2022
- 10 Aug 2022 Pharmacodynamics data from preclinical studies in Neurodegenerative disorders and depressive disorders released by Psilera